Kayla Weaver
Medical · Athens, GANPI 1003110081
Payments from drug & device makers
Across 480 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$915
- QOL Medical, LLC$533
- Takeda Pharmaceuticals U.S.A., Inc.$491
- Bristol Myers Squibb$340
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,67199%
- Education$1311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 102 | $1,900 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 120 | $1,680 |
| Johnson & Johnson(2 entities) | 39 | $915 |
| QOL Medical, LLC | 21 | $533 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $491 |
| Bristol Myers Squibb | 25 | $340 |
| Regeneron Healthcare Solutions, Inc. | 13 | $277 |
| Sanofi | 12 | $263 |
| Ardelyx, Inc. | 16 | $237 |
| Pfizer | 13 | $229 |
| Intercept Pharmaceuticals, Inc. | 13 | $222 |
| Janssen Scientific Affairs, LLC | 2 | $208 |
| Ipsen Biopharmaceuticals, Inc | 6 | $206 |
| Lilly USA, LLC | 9 | $173 |
| Gilead | 6 | $116 |
| Novo Nordisk | 6 | $114 |
| Merck | 7 | $101 |
| Vivus LLC | 5 | $93 |
| Phathom Pharmaceuticals, Inc. | 5 | $91 |
| Nestle Healthcare Nutrition Inc. | 5 | $91 |
| Ferring Pharmaceuticals Inc. | 5 | $69 |
| Madrigal Pharmaceuticals | 3 | $61 |
| Ironwood Pharmaceuticals, Inc | 3 | $55 |
| Organon | 3 | $54 |
| Amgen | 2 | $46 |
| Celltrion USA Inc. | 2 | $43 |
| Evoke Pharma, Inc. | 3 | $39 |
| Exact Sciences | 2 | $32 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Intra-sana Laboratories | 2 | $25 |
| Sandoz | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,801 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 53 | $161,269 |
| CreonLipase/Protease/Amylase | 67 | $147,662 |
| LinzessLinaclotide | 105 | $98,395 |
| ZenpepLipase/Protease/Amylase | 19 | $68,604 |
| Dexlansoprazole DrDexlansoprazole | 122 | $42,479 |
| TrulancePlecanatide | 37 | $33,637 |
| MotegrityPrucalopride Succinate | 21 | $21,115 |
| Budesonide DrBudesonide | 77 | $12,522 |
| VoqueznaVonoprazan Fumarate | 11 | $12,048 |
| MovantikNaloxegol Oxalate | 12 | $11,668 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 133 | $8,442 |
| Lubiprostone | 55 | $8,220 |
| Alosetron Hcl | 13 | $7,209 |
| Ondansetron Hcl | 53 | $6,002 |
| Pantoprazole Sodium | 494 | $5,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,900 | $246,057172 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,680 | $194,90690 claims |
| Aimmune Therapeutics, Inc.Zenpep | $18 | $68,60419 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $491 | $25,06833 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $91 | $12,04811 claims |
| Redhill Biopharma Inc.Movantik | $18 | $11,66812 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $69 | $2,25013 claims |
| SandozLansoprazole | $23 | $1,47327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.
Other medical in Athens
- Charles DavisAthens$17K
- Anna McFatherAthens$13K
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.